NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
7 trialsNCT05350163 2024-12-10
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Phase 1 Terminated
NCT06435910 2024-06-10
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1 Recruiting
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT01199718 2011-06-15
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Cylene Pharmaceuticals
Phase 1 Unknown
NCT00988312 2009-10-02
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
University Hospital Carl Gustav Carus
Phase 1 Completed